BioTuesdays

Tag - BTIG

Acutes-Medical-Logo
Markets

Analysts cut Acutus Medical PT to $8 and $10

Analysts for BTIG and Canaccord Genuity reduced their price targets for Acutus Medical (NASDAQ:AFIB) to $8 from $20 and to $10 from $18, respectively, but maintain their “buy” ratings, after the company reported third...

November 12, 2021
Sigilon Therapeutics
Markets

BTIG starts Sigilon Therapeutics at buy; PT $14

BTIG launched coverage of Sigilon Therapeutics (NASDAQ:SGTX) with a “buy” rating and price target of $14. The stock closed at $5.38 on Oct. 28. Sigilon is developing shielded living therapeutics (SLTs) as a “functional...

October 29, 2021
Vicarious-Surgical
Markets

BTIG starts Vicarious Surgical at buy; PT $15

BTIG initiated coverage of Vicarious Surgical (NYSE:RBOT) with a “buy” rating and $15 price target. The stock closed at $10.57 on Oct.15. Vicarious Surgical is a pre-commercial development-stage surgical robotics...

October 18, 2021
Neuronetics Logo
Markets

BTIG cuts Neuronetics to neutral

BTIG downgraded Neuronetics (NASDAQ:STIM) to “neutral” and removed its price target, citing disappointing third quarter preliminary revenue and “perplexing fourth quarter guidance.” The stock closed at $6.40 on Oct. 12...

October 13, 2021
Sonnet-BioTherapeutics
Markets

BTIG starts Sonnet BioTherapeutics at buy; PT $5

BTIG launched coverage of Sonnet BioTherapeutics (NASDAQ:SONN) with a “buy” rating and price target of $5. The stock closed at 56 cents on Sept. 14. Sonnet is an early-stage biotechnology company working to develop...

September 15, 2021
Talis-Logo
Markets

BTIG cuts Talis Biomedical to neutral without PT

BTIG downgraded Talis Biomedical (NASDAQ:TLIS) to “neutral” from “buy” and removed its price target after president, CEO, director and co-founder, Brian Coe, stepped down from the board and executive. The stock closed...

September 1, 2021
Rani-Therapeutics
Markets

Analysts start Rani Therapeutics at buy; PT $24

Analysts for Stifel and BTIG launched coverage of Rani Therapeutics (NASDAQ:RANI) with “buy” ratings and price targets of $24, respectively. The stock closed at $17.76 on Aug. 24. “Rani appears to have cracked the...

August 25, 2021
RxSight
Markets

Analysts start RxSight at buy

Analysts for BTIG and SVB Leerink launched coverage of RxSight (NASDAQ:RXST) with “buy” ratings and price targets of $28 and $20, respectively. The stock closed at $11.94 on Aug. 23. RxSight has developed the Light...

August 24, 2021
CTIBiopharmaLogo
Markets

BTIG starts CTI Biopharma at buy; PT $7

BTIG initiated coverage of CTI Biopharma (NASDAQ:CTIC) with a “buy” rating and price target of $7. The stock closed at $2.80 on Aug. 6. CTI is a biotechnology company engaged in the development of therapeutics for blood...

August 9, 2021